Richardus J H, Smith T C
Lepr Rev. 1989 Dec;60(4):267-73. doi: 10.5935/0305-7518.19890033.
In order to address the question whether hypersensitivity reactions to dapsone are becoming more frequent, the clinical data of 7300 leprosy patients treated between 1949 and September 1988 at the McKean Rehabilitation Centre in Thailand were reviewed. Information from the period 1949 to 1969 was too incomplete to allow conclusions. The incidence of hypersensitivity reactions to dapsone between 1970 and 1982 was 0.3%. From 1982 (with the introduction of multidrug therapy) to September 1988, the incidence was 3.6%; a tenfold increase compared with the previous period. Of the 19 cases seen since 1982, 12 were diagnosed as Dapsone syndrome. Of a total of 13 patients seen since 1980 with Dapsone syndrome, 3 ended fatally, indicating the severity of the complication. The question is raised whether an unexplained drug interaction with rifampicin is responsible for the increase of hypersensitivity reactions to dapsone in patients treated for leprosy.
为了探讨对氨苯砜的过敏反应是否变得更加频繁,我们回顾了1949年至1988年9月期间在泰国麦克凯恩康复中心接受治疗的7300例麻风病患者的临床资料。1949年至1969年期间的信息过于不完整,无法得出结论。1970年至1982年期间对氨苯砜过敏反应的发生率为0.3%。从1982年(采用多药联合疗法)到1988年9月,发生率为3.6%;与前一时期相比增加了十倍。自1982年以来所见的19例病例中,12例被诊断为氨苯砜综合征。自1980年以来共见到13例氨苯砜综合征患者,其中3例死亡,表明该并发症的严重性。有人提出疑问,在接受麻风病治疗的患者中,与利福平的一种无法解释 的药物相互作用是否是导致对氨苯砜过敏反应增加的原因。